GH Research PLC (GHRS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GH Research PLC (GHRS) has a cash flow conversion efficiency ratio of -0.044x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.26 Million) by net assets ($279.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GH Research PLC balance sheet independence to measure how much of total assets are equity-financed.
GH Research PLC - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how GH Research PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check GHRS cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
GH Research PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GH Research PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Emlak Konut Gayrimenkul Yatirim Ortakligi AS
IS:EKGYO
|
-0.270x |
|
Beach Energy Ltd
AU:BPT
|
0.140x |
|
Europris ASA
OL:EPR
|
0.341x |
|
Kohl's Corporation
NYSE:KSS
|
0.185x |
|
Shipping Corporation Of India Limited
NSE:SCI
|
0.085x |
|
Goosehead Insurance Inc
NASDAQ:GSHD
|
-0.112x |
|
Dar Global Plc
LSE:DAR
|
0.112x |
|
Eaglerise Electric & Electronic China Co Ltd Class A
SHE:002922
|
0.039x |
Annual Cash Flow Conversion Efficiency for GH Research PLC (2019–2025)
The table below shows the annual cash flow conversion efficiency of GH Research PLC from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market value of GH Research PLC.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $279.70 Million | $-43.55 Million | -0.156x | +34.10% |
| 2024-12-31 | $178.95 Million | $-42.28 Million | -0.236x | -55.21% |
| 2023-12-31 | $218.97 Million | $-33.34 Million | -0.152x | -45.17% |
| 2022-12-31 | $249.82 Million | $-26.20 Million | -0.105x | -90.20% |
| 2021-12-31 | $277.18 Million | $-15.28 Million | -0.055x | +5.33% |
| 2020-12-31 | $5.67 Million | $-330.00K | -0.058x | +91.94% |
| 2019-12-31 | $400.00K | $-289.00K | -0.723x | -- |
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II… Read more